Keywords: Astellas, Tarceva, sNDA, Janssen, Preziata, HIV-1, Biogen Idec, Elan, Tysabri, New indication, QRxPharma, MoxDuo, NDA filing, USA, Europe
Regulatory briefs from Astellas, Janssen, Biogen and Elan, and QRxPharma
Article | 17 January 2013
The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says the US Food and Drug Administration has accepted ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
